2 months ago
Kris Jenner couldn't be happier after adding peptides to her beauty routine.
The Keeping Up With the Kardashians matriarch, who recently turned 70, has revealed that she's been using peptides to help keep her hair looking healthy and full—more than a year after getting a reported $100,000 facelift.
Jenner has been using Omi's Hair Growth Peptides, a product she's not just a fan of but also has a financial stake in.
Earlier this year, she opened up about the product in a sponsored Instagram Story, saying she initially started taking the peptides in gummy form.
"I started taking [them] as a gummy form, two a day, and it pretty much changed my life," she said.
#hair #using #product
The Keeping Up With the Kardashians matriarch, who recently turned 70, has revealed that she's been using peptides to help keep her hair looking healthy and full—more than a year after getting a reported $100,000 facelift.
Jenner has been using Omi's Hair Growth Peptides, a product she's not just a fan of but also has a financial stake in.
Earlier this year, she opened up about the product in a sponsored Instagram Story, saying she initially started taking the peptides in gummy form.
"I started taking [them] as a gummy form, two a day, and it pretty much changed my life," she said.
#hair #using #product
2 months ago
The Los Angeles County Medical Examiner's full autopsy report on late Memphis Grizzlies veteran forward and former Phoenix Desert Vista standout Brandon Clarke was released Monday, Aug. 24. Clarke had cocaine, heroin, oxycodone, and multiple other medications "within therapeutic levels," per the report obtained by USA Today Sports.
Clarke's roommate told officials that Clarke had a "history of drug use" and underwent multiple rehabilitation stints for drug addiction, according to the report's synopsis.
Clarke died at his San Fernando Valley residence on May 11. He was 29 years old. The cause of death was an accidental overdose from the "effects of heroin and cocaine" in Clarke's system, which matched the medical examiner's initial statement about Clarke on Aug. 7.
Los Angeles Fire Department officials listed in the incident's early reports that he was found unresponsive and declared dead at the scene.
Drug paraphernalia was found at Clarke's home, according to the synopsis report. That included "vape devices, cannabis products, prescription medications, injectable peptides, syringes, a box of Narcan, blister packets of medications, vitamins and other medical evidence." Also, there was a plate with an "unknown white powdery substance and a hotel keycard" found in the kitchen.
#medical #drug
Clarke's roommate told officials that Clarke had a "history of drug use" and underwent multiple rehabilitation stints for drug addiction, according to the report's synopsis.
Clarke died at his San Fernando Valley residence on May 11. He was 29 years old. The cause of death was an accidental overdose from the "effects of heroin and cocaine" in Clarke's system, which matched the medical examiner's initial statement about Clarke on Aug. 7.
Los Angeles Fire Department officials listed in the incident's early reports that he was found unresponsive and declared dead at the scene.
Drug paraphernalia was found at Clarke's home, according to the synopsis report. That included "vape devices, cannabis products, prescription medications, injectable peptides, syringes, a box of Narcan, blister packets of medications, vitamins and other medical evidence." Also, there was a plate with an "unknown white powdery substance and a hotel keycard" found in the kitchen.
#medical #drug
3 months ago
Hims & Hers Health is planning to sell compounded peptides, the company said in a Monday earnings call.
The company's CEO, Andrew Dudum, said in the earnings call that it was "currently developing a best-in-class peptides experience, including U.S. manufactured products, clinical-led guidance, and ongoing blood testing."
Dudum said in the call that the company had begun testing for the ingredients in some peptides, adding that "this will ensure we can bring them to the market with a safe, verified supply chain if the [Food and Drug Administration (FDA)] decides to allow them for compounding."
Injectable peptides, which are combinations of amino acids, recently became popular among many health-conscious Americans, partially due to enthusiasm from Health and Human Services (HHS) Secretary Robert F. Kennedy.
Kennedy has said he is "a big fan of peptides" and has vowed action to widen their accessibility.
#Peptides #Health #call #hims
The company's CEO, Andrew Dudum, said in the earnings call that it was "currently developing a best-in-class peptides experience, including U.S. manufactured products, clinical-led guidance, and ongoing blood testing."
Dudum said in the call that the company had begun testing for the ingredients in some peptides, adding that "this will ensure we can bring them to the market with a safe, verified supply chain if the [Food and Drug Administration (FDA)] decides to allow them for compounding."
Injectable peptides, which are combinations of amino acids, recently became popular among many health-conscious Americans, partially due to enthusiasm from Health and Human Services (HHS) Secretary Robert F. Kennedy.
Kennedy has said he is "a big fan of peptides" and has vowed action to widen their accessibility.
#Peptides #Health #call #hims
3 months ago
(NewsNation) — ALS, or amyotrophic lateral sclerosis, is a fatal neurological disease with no cure. For people who carry genetic mutations linked to the disease, one of the biggest challenges is not knowing when symptoms might begin.
New research funded by the National Institutes of Health could help change that.
Researchers have developed a blood test that may predict when an at-risk person is likely to develop ALS symptoms, providing a potential window for preventive treatment before irreversible nerve damage occurs.
The study identified protein markers in the blood that can help predict the onset of symptoms, a transition known as phenoconversion.
Dr. Anthony Youn says popular peptides 'aren't studied enough' in humans
#Help #blood #national #researchers
New research funded by the National Institutes of Health could help change that.
Researchers have developed a blood test that may predict when an at-risk person is likely to develop ALS symptoms, providing a potential window for preventive treatment before irreversible nerve damage occurs.
The study identified protein markers in the blood that can help predict the onset of symptoms, a transition known as phenoconversion.
Dr. Anthony Youn says popular peptides 'aren't studied enough' in humans
#Help #blood #national #researchers
3 months ago
South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.
That FDA approval was followed in 2016 by a Certificate of Good Manufacturing Practice (GMP) compliance from the EMA for biologics drug substance and drug product, and the company now has over 450 approvals from regulators around the world. The expansion of Samsung's manufacturing licences is mirrored in the growth of its performance, which saw it achieve revenues of $3.1bn (Won4,557bn) in 2025, a 30% increase from the previous year.
Until now, that work has been centred on the Songdo Bio Cluster in the South Korean city of Incheon, where Samsung will have three campuses, having recently acquired land for Bio Campus III, which will be set aside for future modalities including work on cell and gene therapies and vaccines. The cluster will also be the location for Samsung's forthcoming open innovation centre, which is due to open in 2027 and is being built in partnership with Lilly Gateway Labs. But a key part of the company's plans for continued growth involves adding capacity outside its home country.
On 20 July 2026, Samsung unveiled its plans for the $1.8bn (SFr1.46bn) acquisition of PolyPeptide Group, which specialises in peptide-based active pharmaceutical ingredients (APIs) and produces one third of the commercially approved peptides in the world. In addition to expanding Samsung's capabilities beyond antibodies and ADCs and into peptide therapeutics, including GLP-1s, its deal with the Swiss CDMO also comes with a network of sites across Sweden, Belgium, France, the US, and India, together with a corporate office in Switzerland and an innovation centre in Strasbourg, France.
The PolyPeptide deal is expected to close before the end of 2026, when it will build on Samsung's first major M&A transaction of the year. That saw the South Korean CDMO complete its $280M acquisition of GSK's Rockville, MD, US facility on March 31, 2026. The agreement gave Samsung its first US manufacturing presence and an additional 60,000L of drug substance capacity, increasing its global capacity to 845,000L.
#south
That FDA approval was followed in 2016 by a Certificate of Good Manufacturing Practice (GMP) compliance from the EMA for biologics drug substance and drug product, and the company now has over 450 approvals from regulators around the world. The expansion of Samsung's manufacturing licences is mirrored in the growth of its performance, which saw it achieve revenues of $3.1bn (Won4,557bn) in 2025, a 30% increase from the previous year.
Until now, that work has been centred on the Songdo Bio Cluster in the South Korean city of Incheon, where Samsung will have three campuses, having recently acquired land for Bio Campus III, which will be set aside for future modalities including work on cell and gene therapies and vaccines. The cluster will also be the location for Samsung's forthcoming open innovation centre, which is due to open in 2027 and is being built in partnership with Lilly Gateway Labs. But a key part of the company's plans for continued growth involves adding capacity outside its home country.
On 20 July 2026, Samsung unveiled its plans for the $1.8bn (SFr1.46bn) acquisition of PolyPeptide Group, which specialises in peptide-based active pharmaceutical ingredients (APIs) and produces one third of the commercially approved peptides in the world. In addition to expanding Samsung's capabilities beyond antibodies and ADCs and into peptide therapeutics, including GLP-1s, its deal with the Swiss CDMO also comes with a network of sites across Sweden, Belgium, France, the US, and India, together with a corporate office in Switzerland and an innovation centre in Strasbourg, France.
The PolyPeptide deal is expected to close before the end of 2026, when it will build on Samsung's first major M&A transaction of the year. That saw the South Korean CDMO complete its $280M acquisition of GSK's Rockville, MD, US facility on March 31, 2026. The agreement gave Samsung its first US manufacturing presence and an additional 60,000L of drug substance capacity, increasing its global capacity to 845,000L.
#south
4 months ago
Jenny Mollen has revealed she went through a "harrowing" experience while taking a GLP-1 weight loss drug.
The episode left her then-husband Jason Biggs "screaming like it's a horror movie", she shared on the latest episode of the Let's Talk Off Camera With Kelly Ripa podcast.
"I was microdosing the GLPs. I was also taking other peptides," Mollen recalled of the June 2025 incident. But I think that something happens with your period. Maybe it's just the perimenopausal situation.
"Suddenly I was, like, hemorrhaging. It was blood clots the size of dinosaur eggs. It was so scary," she continued, adding that she "felt like I was laying an egg" when she went to the bathroom. "So I run to the bathroom and I am literally sitting on the toilet and I hear this plop and just blood everywhere."
When Biggs came to help, he joined in on the panic moment and started screaming too.
Mollen didn't immediately go to the hospital but, by that night, her condition had worsened and she knew she was losing too much blood.
The episode left her then-husband Jason Biggs "screaming like it's a horror movie", she shared on the latest episode of the Let's Talk Off Camera With Kelly Ripa podcast.
"I was microdosing the GLPs. I was also taking other peptides," Mollen recalled of the June 2025 incident. But I think that something happens with your period. Maybe it's just the perimenopausal situation.
"Suddenly I was, like, hemorrhaging. It was blood clots the size of dinosaur eggs. It was so scary," she continued, adding that she "felt like I was laying an egg" when she went to the bathroom. "So I run to the bathroom and I am literally sitting on the toilet and I hear this plop and just blood everywhere."
When Biggs came to help, he joined in on the panic moment and started screaming too.
Mollen didn't immediately go to the hospital but, by that night, her condition had worsened and she knew she was losing too much blood.
5 months ago
(NewsNation) — Peptides are surging in popularity across the wellness and fitness ******* e, and now there's one that supporters claim could help reduce signs of aging.
GHK-Cu, a copper peptide that naturally occurs in the body, is gaining momentum as a skin rejuvenation product touted by celebrities and social media influencers.
First discovered in human plasma in 1973, the compound was found to help old liver tissue act as if it were young again. However, as the body ages, it produces less of it.
Peptides are naturally occurring in everyone, but with advances in medical technology, synthetic peptides have become popular.
Could stopping and restarting GLP-1 drugs have side effects?
GHK-Cu, a copper peptide that naturally occurs in the body, is gaining momentum as a skin rejuvenation product touted by celebrities and social media influencers.
First discovered in human plasma in 1973, the compound was found to help old liver tissue act as if it were young again. However, as the body ages, it produces less of it.
Peptides are naturally occurring in everyone, but with advances in medical technology, synthetic peptides have become popular.
Could stopping and restarting GLP-1 drugs have side effects?
1 yr. ago
SMS Pharmaceuticals FY25 results: PAT up 39%, Rs 250cr capex planned for FY26 growth https://business-news-toda... #SMSPharma #PharmaStocks #APIMarket #CMOBusiness #Hyderabad #SMSPharmaceuticals #IndiaPharma #EarningsResults #PharmaEarnings #BackwardsIntegration #Peptides #Capex2025
https://business-news-toda...
https://business-news-toda...
